INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.33 USD | -4.32% |
|
-1.48% | -18.40% |
| 03-21 | Transcript : InflaRx N.V. - Special Call | |
| 03-21 | InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 932K 998K 1.36M | Sales 2025 * | 2.22M 2.38M 3.24M | Capitalization | 73.36M 78.62M 107M |
|---|---|---|---|---|---|
| Net income 2024 * | -58M -62.16M -84.87M | Net income 2025 * | -62M -66.45M -90.72M | EV / Sales 2024 * | 20.3 x |
| Net cash position 2024 * | 54.44M 58.34M 79.66M | Net cash position 2025 * | 10.59M 11.35M 15.5M | EV / Sales 2025 * | 28.3 x |
| P/E ratio 2024 * |
-1.36
x | P/E ratio 2025 * |
-1.44
x | Employees | 62 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on InflaRx N.V.
More recommendations
More press releases
More news
| 1 day | -4.32% | ||
| 1 week | -1.48% | ||
| Current month | -13.64% | ||
| 1 month | -13.64% | ||
| 3 months | -13.64% | ||
| 6 months | -22.67% | ||
| Current year | -18.40% |
1 week
1.26
1.46
1 month
1.241.68
Current year
1.242.10
1 year
1.145.20
3 years
0.787.25
5 years
0.7847.29
10 years
0.7853.10
| Managers | Title | Age | Since |
|---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 20-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.33 | -4.32% | 169,301 |
| 24-04-25 | 1.39 | +2.21% | 146,063 |
| 24-04-24 | 1.36 | 0.00% | 71,453 |
| 24-04-23 | 1.36 | -0.73% | 97,209 |
| 24-04-22 | 1.37 | +1.48% | 116,449 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.246
EUR
Average target price
7.372
EUR
Spread / Average Target
+491.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.40% | 78.31M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.61% | 22.15B | |
| -17.37% | 21.02B | |
| -8.54% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- IFRX Stock
